Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

Click here to view original web page at

Wikimedia Commons

s the clinical and regulatory update Mirati Therapeutics (MRTX) provided Monday for its lead lung cancer cancer immunotherapy drug really positive? That’s what the biotech chose to say in the headline of its press release. The details, disclosed for the first time, are far more concerning.

IMirati is one of many biotechs developing new immunotherapy drugs that are meant to combine with existing checkpoint inhibitors like Merck’s Keytruda or Bristol-Myers Squibb’s Opdivo. The idea is that combinations of immunotherapies will provide greater benefit to a larger group of patients than checkpoints can achieve on their own.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.